Selected Publications

See ResearchNet and Google Scholar


Cannabis and endocannabinoid system

Gobbi G, Atkin T, Zytynski T, et al.
Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis.
JAMA Psychiatry. Published online February 13, 2019. doi:10.1001/jamapsychiatry.2018.4500

De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, Aboud M, Maione S, Comai S, Gobbi G.
Cannabidiol modulates serotonergic transmission and prevents allodynia and anxiety-like behavior in a model of neuropathic pain.
Pain. 2018 Aug 27; [Epub ahead of print] PMID: 30157131

Bambico FR, Hattan PR, Garant JP, Gobbi G.
Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission.
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):88-96. PMID: 22386778

Bambico F, Cassano T., Dominguez-Lopez S., Katz N., Walker CD., Piomelli D., Gobbi G.
Genetic Deletion of Fatty Acid Amide Hydrolase Alters Emotional Behavior and Serotonergic Transmission in the Dorsal Raphe, Prefrontal Cortex, and Hippocampus.
Neuropsychopharmacology. 2010 Sep; 35(10):2083-100.  PMID: 20571484

Bambico F, Nhuyen NT., Katz N., Gobbi G.
Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission.
Neurobiol Dis. 2010 Mar; 37(3):641-655. PMID: 19969082

Hill M., Hillard C.J., Bambico R.F., Patel S., Gorzalka B., Gobbi G.
The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants.
Trends Pharmacol Sci. 2009 Sep.;30(9): 484-93. PMID: 19732971

Bambico FR, Duranti A, Tontini A, Tarzia G, Gobbi G.
Endocannabinoids in the treatment of mood disorders: evidence from animal models.
Curr Pharm Des. 2009; 15(14):1623-46. PMID: 19442178

Bambico F and Gobbi G.
The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets.
Expert Opin Ther Targets. 2008 Nov; 12(11):1347-66. PMID: 18851692

Di Marzo V, Gobbi G, Szallasi A.
Brain TRPV1: a depressing TR(i)P down memory lane?
Trends Pharmacol Sci. 2008 Dec; 29(12):594-600. PMID: 18947889

Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D.
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.
Proceeding of National Academy of Sciences of the USA. 2005 Dec 20;102(51) : 18620-5. PMID: 16352709

 

Melatonin and its receptors

Comai S, Lopez-Canul M, De Gregorio D, Posner A, Ettaoussi M, Guarnieri F, Gobbi G. Melatonin MT1 receptor as a novel target in neuropsychopharmacology: MT1 ligands, pathophysiological and therapeutic implications and perspectives. Pharmacological research. 25 Apr 2019. https://doi.org/10.1016/j.phrs.2019.04.015

Gabriella Gobbi, Stefano Comai. Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep. Journal of pineal research. 2019 Apr. https://doi.org/10.1111/jpi.12544.

Gabriella Gobbi, Stefano Comai. Differential function of Melatonin MT1 and MT2 receptors in REM and NREM sleep. Frontiers in Endocrinology. 2019. doi: 10.3389/fendo.2019.00087

Comai S, Posa L, Ochoa-Sanchez R, Spadoni G, Gobbi G. Neuropsychopharmacological properties of novel melatonin MT1 receptor ligands. European Neuropsychopharmacology. 2017 Oct 10.  DOI: https://doi.org/10.1016/S0924-977X(17)31098-2

Gobbi G, Lopez-Canul M, Ochoa-Sanchez R, Comai S. Anxiolytic, hypnotic and analgesic properties of melatonin MT2 receptor partial agonists. European Neuropsychopharmacology. 2017 Oct 10. DOI: https://doi.org/10.1016/S0924-977X(17)31099-4

Posa L., De Gregorio D., Gobbi G., Comai S. Targeting melatonin MT2 receptors: A novel pharmacological avenue for inflammatory and neuropathic pain. Curr Med Chem. 2017 Feb 8. doi: 10.2174/0929867324666170209104926.

Lopez-Canul M., Palazzo E., Dominguez-Lopez S., Luongo L., Lacoste B., Comai S., Boccella S., Angeloni D., Fraschini F., Spadoni G, Bedini AL, Tarzia G., Maione S., Granados-Soto V., Gobbi G. Selective Melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways.
Pain. 2015 Feb;156(2):305-17. doi: 10.1097/01.j.pain.0000460311.71572.5f. PMID: 25599452

Comai S., Ochoa-Sanchez R, Dominguez-Lopez S., Bambico FR., Gobbi G.   Melancholic-like behaviors and circadian neurobiological abnormalities in MT1 receptor knockout mice 
Int J Neuropsychopharmacology. 2015 Jan 31;18(3). pii: pyu075. doi: 10.1093/ijnp/pyu075. PMID: 25638817

Ochoa-Sanchez R, Comai S, Gobbi G.   Melatonin, non-selective MT1/MT2 and selective MT2 receptor agonists: differential effects on the 24-hr vigilance states.  
Neuroscience Letters. 2014 Feb 21;561:156-61. PMID: 24406151

Comai S. and Gobbi G.  Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases : a novel target in psychopharmacology.                           
J Psychiatry and Neuroscience. 2013 Aug 27;38(5):130009. doi: 10.1503/jpn.130009. PMID: 23971978

Comai S., Ochoa-Sanchez R., Gobbi G.   Sleep-wake characterization of double MT1 and MT2 receptor knockout mice and comparison with MT1  and MT2 receptor knockout mice.
Behav Brain Research. 2013 Jan 16;243 C:231-238. PMID: 23333399.

Ochoa Sanchez R., Comai S., Rainer Q., Rivara S., Mor M., Bedini AL, Spadoni G, Fraschini F., Tarzia G., Gobbi G.  
Anxiolytic Effects of the Melatonin MT2 Receptor Partial Agonist UCM765: Comparison with Melatonin and Diazepam.  Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2012 Dec 3;39(2):318-25. PMID: 22789661

Ochoa-Sanchez R, Comai S, Lacoste B, Bambico FR, Dominguez-Lopez S, Spadoni G, Rivara S, Bedini A, Angeloni D, Fraschini F, Mor M, Tarzia G, Descarries L, Gobbi G.
Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand.
J Neurosci. 2011 Dec 14;31(50):18439-52. PMID: 22171046

Ochoa-Sanchez R, Rainer Q, Comai S, Spadoni G, Bedini A, Rivara S, Fraschini F, Mor M, Tarzia G, Gobbi G.
Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam.
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):318-25. PMID: 22789661

Domínguez-López S, Mahar I, Bambico FR, Labonté B, Ochoa-Sánchez R, Leyton, M, Gobbi G.
Short term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light-dark cycle.
J Psychopharmacol. 2011 Jul 5. PMID: 21730015

Rivara S, Vacondio F, Fioni A, Silva C, Carmi C, Mor M, Lucini V, Pannacci M, Caronno A, Scaglione F, Gobbi G, Spadoni G, Bedini A, Orlando P, Lucarini S, Tarzia G.
N-(Anilinoethyl) amides: design and synthesis of metabolically stable, selective melatonin receptor ligands.
ChemMedChem. 2009 Oct;4(10):1746-55. PMID: 19728346

 

Anxiety and mood disorders: signalling systems and treatments

Aguilar-Valles A, Haji N, De Gregorio D, Matta-Camacho E, Eslamizade MJ, Popic J, Sharma V, Cao R, Rummel C, Tanti A, Wiebe S, Nuñez N, Comai S, Nadon R, Luheshi G, Mechawar N, Turecki G, Lacaille JC, Gobbi G, Sonenberg N. Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E. Nat Commun. 2018 Jun 25;9(1):2459. doi: 10.1038/s41467-018-04883-5. PMID: 29941989

Bambico FR, Comai S, Diwan M, Hasan SMN, Conway JD, Darvish-Ghane S, Hamani C, Gobbi G, Nobrega JN. High frequency stimulation of the anterior vermis modulates behavioural response to chronic stress: involvement of the prefrontal cortex and dorsal raphe Neurobiol Dis. 2018 Aug;116:166-178. doi: 10.1016/j.nbd.2018.03.011. Epub 2018 May 2. PMID: 29727711

De Gregorio D, Posa L, Ochoa-Sanchez R, McLaughlin R,Maione S, Comai S, Gobbi G. D-lysergic diethylamide modulates dopaminergic neurons of ventral tegmental area via 5-HT1A, D2 and TAAR1 receptors. European Neuropsychopharmacology. 2017 Mar; 27:S53 - S54. PMID: 27544651

 

Paternal separation and depression

Bambico FR, Lacoste B, Hattan PR, Gobbi G.   Father absence in the monogamous California mouse impairs social behavior and modifies dopamine and glutamate synapses in the medial prefrontal cortex. 
Cerebral Cortex. 2013 doi:10.1093/cercor/bht310. PMID: 24304503

 

Clinical Studies

Comai S, Bertazzo A, Vachon J, Daigle M, Toupin J, Côté G, Gobbi G. Trace elements among a sample of prisoners with mental and personality disorders and aggression: correlation with impulsivity and ADHD indices. Journal of trace elements in medicine and biology. 2019 Jan 1. 51, 123-129. https://doi.org/10.1016/j.jtemb.2018.10.008 

Messaoud A, Mensi R, Douki W, Neffati F, Najjar MF, Gobbi G, Valtorta F, Gaha L, Comai S. Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide. World J Biol Psychiatry. 2018 May 23:1-9. doi: 10.1080/15622975.2018.1468031. [Epub ahead of print]. PMID: 29683396

Nuñez NA, Comai S, Dumitrescu E, Ghabrash MF, Tabaka J, Saint-Laurent M, Vida S, Kolivakis T, Fielding A, Low N, Cervantes P, Booij L, Gobbi G. Psychopathological and sociodemographic features in treatment-resistant unipolar depression versus bipolar depression: a comparative study. BMC Psychiatry. 2018 Mar 16;18(1):68. doi: 10.1186/s12888-018-1641-y. PMID: 29548306

Gobbi G, Ghabrash MF, Nuñez N, Tabaka J, Di Sante J, Saint-Laurent M, Vida S, Kolivakis T, Low N, Cervantes P, Booij L, Comai S. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression. Int Clin Psychopharmacol. 2018 Jan;33(1):34-43. doi: 10.1097/YIC.0000000000000196. PMID: 28906325

Ismaylova E, Di Sante J, Szyf M, Nemoda Z, Yu WJ, Pomares FB, Turecki G, Gobbi G, Vitaro F, Tremblay RE, Booij L. Serotonin transporter gene promoter methylation in peripheral cells in healthy adults: neural correlates and tissue specificity. European Neuropsychopharmacology. 27 (10), 1032-1041. https://doi.org/10.1016/j.euroneuro.2017.07.005.

Nuñez NA, Gobbi G. Lurasidone and Mood Stabilizers in Treatment-Resistant Unipolar Depression: A Case Report Study. J Clin Psychopharmacol. 2017 Apr;37(2):263-264. PMID: 28129315.

Ghabrash MF, Comai S, Tabaka J, Saint-Laurent M, Booij L, Gobbi G.
Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression.
World J Biol Psychiatry. 2016;17(2):165-70. doi: 10.3109/15622975.2015.1073856. Epub 2015 Oct 7. PMID: 26444701

Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, Debonnel G.
Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation.
Eur Neuropsychopharmacol. 2009 Jul;19(7):457-65. PMID: 19345072

Gobbi G., Gaudreau PO, Leblanc N.
Efficacy of Topiramate, Valproate, and Their Combination on Aggression/Agitation Behavior in Patients With Psychosis.
Journal of Clinical Psychopharmacology. 2006 Oct;26(5):467-473. PMID: 16974186

 

Other Reviews

De Gregorio D, Enns JP, Nuñez NA, Posa L, Gobbi G
D-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
Progress in Brain Research. 2018 Aug 31 ; [Chapter in press] ; https://doi.org/10.1016/bs.pbr.2018.07.008

Atkin T, Comai S, Gobbi G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacol Rev. 2018 Apr;70(2):197-245. doi: 10.1124/pr.117.014381. Review. PMID: 29487083

Atkin T, Nuñez N, Gobbi G. Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder. J Child Psychol Psychiatry. 2017 Aug;58(8):865-879. Epub 2017 May 5. Review. PMID: 28474733

De Gregorio D, Comai S, Posa L, Gobbi G. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology. Int J Mol Sci. 2016 Nov 23;17(11). pii: E1953. Review.PMID: 27886063.

 

Commentaries

Gobbi, Gabriella. A role for cannabidiol in psychiatry? Keep calm and follow the drug development rules. The World Journal of Biological Psychiatry. 2019 Apr 11. https://doi.org/10.1080/15622975.2019.1584680